Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320814 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00320814 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT00320814, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
To assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with diabetic macular edema.
Interventions
- DRUG VEGF Trap-Eye
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320814
The ClinicalTrials.gov registry entry for NCT00320814 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VEGF Trap-Eye is the first listed.
NCT00320814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00320814 about?
NCT00320814 is a clinical study titled "Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema". To assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with diabetic macular edema.
What is the current status of trial NCT00320814?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2006-04. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00320814?
The interventions under investigation include: VEGF Trap-Eye (DRUG).
Who is sponsoring clinical trial NCT00320814?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.